1967 results about "Hyperlipidemia" patented technology

This invention describes the use of pharmaceutical compositions, which comprise three components of which at least one is a slow release therapeutic agent. Such useful compositions are applicable for the treatment of humans suffering from diabetic, hypertensive, cardiovascular, hyperlipidemic conditions and their associated disorders thereof. Combination therapy has the advantages of better patient compliance; better therapeutic efficacy coupled with a reduction in the dose for some of the individual therapeutic agent(s) in the combination.

A dibenzylamine compound represented by the formula (1)

wherein R¹ and R² are each a C_1-6 alkyl group optionally substituted by halogen atoms and the like; R³, R⁴ and R⁵ are each a hydrogen atom, a halogen atom and the like, or R³ and R⁴ may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is

—N(R⁷) (R⁸) and the like; ring B is an aryl group or a heterocyclic residue; R⁶ is a hydrogen atom, a halogen atom, a nitro group, a C_1-6 alkyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.

Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.

The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.

The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.

Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals.

Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals. Also provided are compositions and methods for combination therapy employing ileal bile acid transport inhibitors and EG Co-A reductase inhibitors for the treatment of hyperlipidemic conditions.

The invention belongs to the technical field of affinal drug and diet formulas and new resource food, and particularly provides blood fat-reducing medical science formula food, specific medical formula food or non-specific medical formula food. The formula food is prepared by performing reasonable compatibility on multiple affinal drug and diet traditional Chinese medicines according to the traditional Chinese medicine essence theory and mixing drug-diet dual purpose traditional Chinese medicine extract essence extracted through a semi-bionic extraction method, multiple microencapsulated probiotics, oligopeptides extracted through biological enzymolysis, prebiotics, amino acid, carbohydrate, fat with a health-care function, multiple vitamins and mineral substances according to the requirements of a 'special medial-purpose formula food general rule' by combining the constitutive characters of hyperlipidemia patients; the formula food not only can serve as a single nutrition source to meet the nutritional requirement of the hyperlipidemia patients, but also achieves the effects of reducing total cholesterol, reducing serum triglyceride, reducing an atherosclerosis index, reducing blood pressure, reducing blood sugar, reducing fat to lose weight and enhancing the immunity.

The invention relates to flour suitable for obese patients. The special meal flour for preparing foods for obese patients is prepared in the by uniformly mixing power made of rhizoma polygonati, semencassiae, gingko, raw hawthorn, tuckahoe, white lablab bean, Chinese yam and semen coicis with whole wheat (with a husk), oat, azuki bean and black bean. The flour can be used for producing various foods suitable for obese patients to eat as a principle food. The flour has the obvious effects of systemically adjusting lipid metabolism and glucose metabolism, losing weight, lowering blood fat, improving microcirculation and eliminating radicals. The special meal flour is suitable for patients with adiposity, adiposis hepatica, hyperlipemia, high blood viscosity, hypertension and diabetes mellitus, and for middle-aged and old people to keep healthy and eat.

The invention relates to blood lipid-lowering active fractions of forsythia suspensa and a preparation method and use of the same. The active fractions are ethyl acetate fractions obtained by concentrating an extract which is extracted from forsythia suspensa leaves by acetone and water. The compound of phillygenin prepared by the invention and the active fractions, namely the ethyl acetate fractions, at which the phillygenin is positioned have good antioxidant activity in vitro. In-vivo experiments show that the ethyl acetate fractions and the phillygenin can lower total cholesterols and low-density lipoprotein cholesterin in the blood serum of a mouse with hyperlipidemia and can lower blood lipid level by an oxidative approach (raising superoxide dismutase SOD and lowering malonydialdehyde MDA). In addition, the ethyl acetate fractions have a better effect of reducing the total cholesterols in the blood serum of the mouse than the phillygenin and cassia seed blood lipid-lowering tablets. The ethyl acetate fractions of the forsythia suspensa leaves can be further developed to play a role in the multi- target co-prevention and treatment of hyperlipidemia and other diseases and have a good application prospect.

The invention relates to a biological fermentation composition with an anti-cancer effect. The biological fermentation composition is prepared by using a method comprising the following steps: a, preparing a culture medium mixed solution; b, sterilizing; c, cooling; d, inoculating to obtain a fermentation solution; and e, standing to obtain the biological fermentation composition with the anti-cancer effect. The composition disclosed by the invention can be used for improving the in-vivo micro-ecological environment, balancing and regulating effective microbial communities in intestinal canals, repairing damaged cells, replenishing various in-vivo active bio-enzymes, amino acids, nucleic acids, trace elements and the like, improving the immunity of a human body, preventing diseases, effectively inhibiting cancer cells and stopping the dispersion and development of the cancer cells. Meanwhile, the biological fermentation composition can be used for improving an acidic physique to be a weak alkaline physique, is particularly suitable for the cancer crowd, the crowd with hypertension, hyperlipidemia and hyperglycemia and the fat crowd, can be prepared into various dosage forms such as pills, paste, aqueous solutions and the like, and has favorable supportive therapeutic effects on cancer, diabetes, digestive system diseases and the like.

The invention discloses a food composition suitable for a hypertension hyperlipidemia hyperglycemia population, which comprises rice, millet, black rice, yam, lotus roots, oat, tartary buckwheat, lotus seeds, pearl barley, yellow corns, potatoes, hazelnuts, Chinese chestnuts, konjak, black sesame, shiitake mushrooms, lycium barbarum, dried mulberries, dried seedless grapes, dates, salt black beans of soybeans, hawthorn powder, carrot powder, tomato powder, puerarin powder, concentrated whey protein, soy isolate protein, camellia oil, purple perilla seed oil, maltodextrin, L-malic acid, L-carnitine and milk calcium. The invention further discloses a preparation method of the food composition suitable for the hypertension hyperlipidemia hyperglycemia population. After the food composition is taken usually, balanced nutrition can be ensured when effects of effectively reducing a blood pressure, blood fat and blood sugar are achieved; meanwhile, the food composition also has effects of conditioning important organs of a human body, such as livers, kidneys, spleen, stomach, large intestine and the like, protecting the heart, improving blood vessel elasticity, reducing the blood viscosity and preventing the Alzheimer disease.

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.

The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. Roux-en-Y gastric bypass (RYGB)) as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including Type 2 diabetes and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome.

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.

An edible-fiber food for decreasing blood fat and cholesterol, regulating blood sugar, moistening intestine, and preventing constipation, cardiovascular and cerebrovascular diseases, diabetes, intestinal cancer and breast cancer is prepared from water-insoluble fibers (19-80 Wt%) and water-soluble fibers (20-79%).

The invention discloses a lipid-lowering weight-losing lotus leaf beverage and a preparation method thereof. The beverage is prepared from lotus leaves, hawthorn, and cassia seeds. The lotus leaf beverage disclosed in the invention has significant effect on lowering lipid and losing weight, has no toxic or side effects, and is suitable for drinking by vast obesity populations and patients with hyperlipemia.